Diabetes mellitus due to olanzapine use: A case report; [Olanzapin'e baǧli diabetes mellitus: Bir olgu sunumu]

Simple item page
dc.contributor.authorDanaci A.E.
dc.contributor.authorMizrak S.
dc.contributor.authorHekimsoy Z.
dc.contributor.authorIçelli I.
dc.date.accessioned2024-07-22T08:24:43Z
dc.date.available2024-07-22T08:24:43Z
dc.date.issued2003
dc.description.abstractOlanzapine, a serotonin-dopamine-receptor antagonist, is an atypical antipsychotic agent used to treat schizophrenia and other psychotic disorders. It has relatively low frequency of side effects such as sedation, orthostatic hypotension, extrapyramidal symptoms, and anticholinergic side effects. Here, a 32-years-old female patient with schizophrenia who developed diabetes after 3 years of olanzapine treatment is presented. Due to lack of family history and immune marker positivity in the occurrence of diabetes, the condition was attributed to olanzapine treatment. After discontinuation of the treatment DM was improved. Controlled studies are necessary both to elucidate the mechanism by which olanzapine can cause dysregulation of glucose homeostasis, and to develop guidelines for the use of olanzapine in patients with known as well as in patients with risk factors for diabetes.
dc.identifier.issn10177833
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20079
dc.language.isoTurkish
dc.subjectdopamine receptor blocking agent
dc.subjectglucose
dc.subjectolanzapine
dc.subjectserotonin antagonist
dc.subjectadult
dc.subjectarticle
dc.subjectcase report
dc.subjectclinical feature
dc.subjectdiabetes mellitus
dc.subjectdisease course
dc.subjectextrapyramidal symptom
dc.subjectfamily history
dc.subjectfemale
dc.subjectglucose homeostasis
dc.subjecthuman
dc.subjectorthostatic hypotension
dc.subjectrisk factor
dc.subjectschizophrenia
dc.subjectsedation
dc.titleDiabetes mellitus due to olanzapine use: A case report; [Olanzapin'e baǧli diabetes mellitus: Bir olgu sunumu]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu